Iraqi Government Recalls Tainted Cold Medicine Made In India
(Bloomberg) -- Iraqi health authorities are recalling an Indian-made cold syrup that Bloomberg News found to be tainted with a toxic chemical, according to an official in the nation's Kurdistan region.Â
Kocher Younis, head of registration at the Kurdistan Medical Control Agency, said that a nationwide recall began on Wednesday, following one in his region initiated July 30. He provided a copy of a document from the central government's health ministry ordering pharmacies across the country to withdraw the product. No illnesses from consuming the medication have been reported, Younis said.
Contradicting an earlier statement from the Iraqi health ministry, Younis said the product had been authorized for import and sale throughout the country after receiving approval from Kurdistan. A spokesman for the health ministry did not immediately respond to inquiries.
Bloomberg reported last week that a sample of Cold Out purchased in Baghdad in March contained unsafe levels of ethylene glycol, a toxic industrial solvent. The sample was one of 33 purchased by Bloomberg in six countries and tested by Valisure LLC, an independent lab in Connecticut. Bloomberg shared the test results with Iraqi and Indian authorities on July 8.Â
It's the fifth time in a year that testing has found an Indian exporter's drugs to contain excessive levels of ethylene glycol. The chemical was implicated in mass deaths of children who consumed Indian-made cough syrup last year in Gambia and Uzbekistan.Â
The label of the Cold Out sample tested by Valisure indicates it was made by Fourrts (India) Pvt. Ltd. The company has said that a subcontractor manufactured the product in question and that Indian drug regulators were investigating.Â
Several batches of Cold Out were imported to Iraq in recent years, the most recent in January 2023, Younis said. All of them are subject to the recall. He said the Kurdistan Medical Control Agency tested each batch prior to sale, but at least some batches were not tested for impurities such as ethylene glycol because those tests were not considered a requirement.Â
--With assistance from Nayla Razzouk.
More stories like this are available on bloomberg.com
©2023 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.